ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT07392723)

Overview

This Phase 2 randomized, double-blind, placebo-controlled clinical trial investigates whether alpha-linolenic acid (ALA) supplementation from flaxseed oil can prevent cognitive decline in older adults with amnestic mild cognitive impairment (MCI) who carry the APOE4 allele. The trial represents a precision medicine approach targeting the specific metabolic vulnerabilities of [APOE4](/genes/apoe) carriers, who face significantly elevated risk for [Alzheimer's disease](/diseases/alzheimers-disease) and related dementia (ADRD).

The study is sponsored by Rutgers University under the leadership of Dr. Michal Schnaider Beeri, a renowned researcher in the field of Alzheimer's disease epidemiology and prevention. The trial addresses a critical gap in therapeutic options for the preclinical and early symptomatic stages of Alzheimer's disease, particularly in the high-risk APOE4 carrier population.

Pathway / Mechanism Diagram

Overview

This Phase 2 randomized, double-blind, placebo-controlled clinical trial investigates whether alpha-linolenic acid (ALA) supplementation from flaxseed oil can prevent cognitive decline in older adults with amnestic mild cognitive impairment (MCI) who carry the APOE4 allele. The trial represents a precision medicine approach targeting the specific metabolic vulnerabilities of [APOE4](/genes/apoe) carriers, who face significantly elevated risk for [Alzheimer's disease](/diseases/alzheimers-disease) and related dementia (ADRD).

The study is sponsored by Rutgers University under the leadership of Dr. Michal Schnaider Beeri, a renowned researcher in the field of Alzheimer's disease epidemiology and prevention. The trial addresses a critical gap in therapeutic options for the preclinical and early symptomatic stages of Alzheimer's disease, particularly in the high-risk APOE4 carrier population.

Pathway / Mechanism Diagram

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | NCT07392723 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel Assignment |
| Masking | Double-Blind, Quadruple-Masked |
| Enrollment | 20 participants (estimated) |
| Sponsor | Michal Schnaider Beeri, Ph.D., Rutgers University |
| Duration | 6 months |
| Location | Rutgers - Institute for Health, New Brunswick, New Jersey |

Scientific Rationale

APOE4 and Alzheimer's Disease Risk

The [APOE gene](/genes/apoe) encodes apolipoprotein E, a lipid transport protein crucial for cholesterol metabolism and neuronal repair. The APOE4 allele represents the strongest known genetic risk factor for late-onset Alzheimer's disease[@williams2020]:

• Heterozygous APOE4 (one copy): 3-4× increased AD risk
• Homozygous APOE4 (two copies): 10-12× increased AD risk
• Population Frequency: ~25% of population carries at least one APOE4 allele

APOE4 and Lipid Metabolism Dysregulation

APOE4 carriers demonstrate distinct lipid metabolism abnormalities that contribute to neurodegeneration[@yassine2017]:

• Reduced DHA incorporation: APOE4 carriers show decreased brain DHA levels despite adequate dietary intake
• Impaired lipid transport: APOE4 protein has reduced affinity for lipoproteins
• Altered astrocyte function: APOE4 astrocytes demonstrate impaired cholesterol efflux
• Endogenous synthesis limitation: Reduced conversion of ALA to long-chain omega-3s (DHA, EPA)

Blood-Brain Barrier Vulnerabilities

APOE4 is associated with significant blood-brain barrier (BBB) dysfunction[@song2022]:

• Increased BBB permeability: APOE4 carriers show elevated water exchange across BBB
• Reduced MFSD2A expression: The major DHA transporter at the BBB is downregulated
• Cerebrovascular dysfunction: Impaired vascular reactivity and autoregulation
• Pericyte injury: APOE4 is associated with pericyte degeneration

The ALA Hypothesis

This trial tests the hypothesis that high-dose ALA supplementation will:

Intervention Details

Active Treatment Arm

| Parameter | Value |
|-----------|-------|
| Intervention | Flaxseed oil (Alpha-Linolenic Acid) |
| Dose | 2.6g ALA per day |
| Administration | Oral, divided doses |
| Duration | 6 months |
| Formulation | Flaxseed oil softgels or liquid |

Control Arm

| Parameter | Value |
|-----------|-------|
| Intervention | Corn oil (iso-caloric placebo) |
| Administration | Oral, matching volume |
| Duration | 6 months |
| Matching | Caloric content and appearance |

Dose Rationale

The 2.6g/day ALA dose was selected based on:

• Epidemiological data: Higher ALA intake associated with reduced cognitive decline
• Safety profile: Well-tolerated at this dose range
• Conversion potential: Sufficient substrate to potentially enhance endogenous DHA synthesis
• Comparison to prior trials: Within range of doses tested in cardiovascular studies

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Outcome Measures

Primary Endpoints

Global Cognitive Function

• Measure: Change in composite z-scores from baseline to 6 months
• Assessment: Comprehensive neuropsychological battery
• Domains: Memory, executive function, language, visuospatial

Blood-Brain Barrier Integrity

• MRI Metric: Water exchange rate constant (Kw) via MRI
• Significance: Quantifies BBB permeability in vivo
• Technique: Dynamic contrast-enhanced MRI or arterial spin labeling

Peripheral BBB Biomarkers

• MFSD2A: Major facilitator superfamily domain containing 2A (DHA transporter)
• S100B: Calcium-binding protein, marker of BBB disruption
• GFAP: Glial fibrillary acidic protein, astrocyte activation marker

Secondary Endpoints

Cognitive Domain-Specific Outcomes

• Episodic memory: Word recall, story memory
• Executive function: Trail making, Stroop test
• Processing speed: Digit symbol substitution
• Language: Verbal fluency, naming

Cerebrovascular Measures

• Cerebral blood flow: Arterial spin labeling MRI
• Brain vascular reactivity: BOLD signal response to vasodilatory challenge
• White matter hyperintensity volume: FLAIR MRI assessment

Blood Biomarkers

• ADRD biomarkers: p-tau217, Neurofilament Light Chain (NfL)
• Lipid profile: Total cholesterol, LDL, HDL, triglycerides
• Omega-3 markers: ALA, DHA, EPA levels in plasma/red blood cells

Safety Endpoints

• Adverse events monitoring
• Laboratory values (lipid panel, liver function, renal function)
• Vital signs

Mechanism of Action

Omega-3 Fatty Acid Biology

ALA (18:3 n-3) is the plant-based omega-3 fatty acid that serves as a precursor to longer-chain omega-3s:

ALA (18:3 n-3)
↓ Δ6-desaturase (limited in humans)
EPA (20:5 n-3)
↓ elongation
DHA (22:6 n-3)

APOE4-Specific Mechanisms

Lipid Transport Enhancement

• ALA supplementation increases circulating phospholipid content
• Supports astrocyte lipid efflux via APOE-dependent pathways
• Improves neuronal lipid delivery for membrane maintenance

Blood-Brain Barrier Protection

• Omega-3s incorporate into endothelial cell membranes
• Enhances tight junction protein expression
• Upregulates MFSD2A transporter expression

Anti-Inflammatory Effects

• Reduces prostaglandin E2 synthesis
• Decreases NF-κB activation in microglia
• Promotes resolution of neuroinflammation

Neuroprotective Signaling

• DHA is precursor to neuroprotectin D1 (NPD1)
• EPA-derived resolvins promote phagocytic clearance
• Membrane omega-3 enrichment protects against ferroptosis

Expected Outcomes and Clinical Significance

Primary Expected Outcomes

Based on the biological rationale, the trial anticipates:

Clinical Implications

If successful, this trial would establish:

• Precision Prevention: APOE4-targeted nutritional intervention
• Low-Cost Approach: Accessible dietary supplementation for at-risk individuals
• Mechanistic Validation: Proof-of-concept for lipid-based AD prevention
• Combination Potential: Foundation for combination with other prevention strategies

Comparison to Prior Omega-3 Trials

| Trial | Population | Dose | Outcome |
|-------|-----------|------|---------|
| MAPT | MCI/AD | DHA+EPA 2g | Negative |
| VITAL | General >60 | Fish oil 1g | Negative (overall), positive (APOE4) |
| NCT07392723 | APOE4+MCI | ALA 2.6g | Pending |

The key distinction is the focus on APOE4 carriers specifically and the use of ALA rather than preformed DHA/EPA, testing the endogenous conversion enhancement hypothesis.

Cross-References

• [APOE Gene and Alzheimer's Risk](/genes/apoe)
• [APOE4 and Lipid Metabolism](/mechanisms/apoe4-lipid-metabolism)
• [Blood-Brain Barrier in Alzheimer's](/mechanisms/blood-brain-barrier-alzheimers)
• [Omega-3 Fatty Acids and Neuroprotection](/mechanisms/omega-3-neuroprotection)
• [Mild Cognitive Impairment](/diseases/mci)
• [Alzheimer's Disease Prevention](/mechanisms/alzheimers-prevention)
• [Alpha-Linolenic Acid](/nutrients/alpha-linolenic-acid)

External Links

• [ClinicalTrials.gov - NCT07392723](https://clinicaltrials.gov/study/NCT07392723)
• [Rutgers Institute for Health](https://ihrws.rutgers.edu/)
• [APOE4 Carrier Research Registry](https://www.alz.org/)

References